This item is not for sale to consumers.
We are seeking industry partners for licensing, manufacturing
and marketing this technology.
We are seeking industry partners for licensing, manufacturing
and marketing this technology.
The first quantitative,
non-instrumented
whole blood
coagulation test
In the United States today, an estimated two million patients with cardiovascular disease are on oral anticoagulation therapy (Warfarin). These patients must visit a physician's ofice or clinic monthly, bimonthly, or even weekly to monitor their therapy and to allow the physician to make any necessary adjustments to their dosage. Studies have shown that complications related to anticoagulation therapy are estimated to cost $5,700 per patient per year and account for 400,000 hospitalizations and 200,000 deaths annually in the United States. The PortaPT™ coagulation test is the first portable whole blood prothrombin time (PT) measuring device that provides an accurate measurement without the need of an instrument.
The key advantages of this unique, patented technology include:
- Point-of-Care Convenience:
- Healthcare providers can test patients or have patients test themselves at home.
- Accuracy:
- The PortaPT™ coagulation test provides accurate INR readings similar to approved point-of-care anticoagulation tests.
- Fast Results:
- Typically in less than three minutes.
- Easy to use:
- As easy to run as a glucose test and reads like a thermometer